Cancer BiologybioRxivPreprint
Clinical and molecular characterisation of primary refractoriness to atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma.
Pasquale Lombardi, Erik Ramon‐Gil, Leonardo Brunetti…·David James Pinato
This study identifies clinical and molecular features of primary refractoriness to atezolizumab plus bevacizumab in HCC, showing poor outcomes and an immunosuppressive tumor microenvironment.
DOI 10.1101/2025.07.08.663653